We read with great interest the article by Waite et al 1 in the Journal. The authors used a patient case to teach clinical practitioners how to use statin and nonstatin agents in the management of atherosclerotic cardiovascular disease risk. The patient in the case was a 57-year-old woman who had a past medical history of dyslipidemia without atherosclerotic cardiovascular disease or diabetes mellitus. The patient was treated with rosuvastatin 40 mg orally daily for 6 months. Her low-density lipoprotein (LDL) cholesterol decreased from 196 to 130 mg/dL. The authors recommended to further treat the patient with ezetimibe or a PCSK9i (alirocumab or evolocumab) to reach the LDL cholesterol reduction goal-that is, a decrease of 50% from the baseline.
Letter to the Editor
We read with great interest the article by Waite et al 1 in the Journal. The authors used a patient case to teach clinical practitioners how to use statin and nonstatin agents in the management of atherosclerotic cardiovascular disease risk. The patient in the case was a 57-year-old woman who had a past medical history of dyslipidemia without atherosclerotic cardiovascular disease or diabetes mellitus. The patient was treated with rosuvastatin 40 mg orally daily for 6 months. Her low-density lipoprotein (LDL) cholesterol decreased from 196 to 130 mg/dL. The authors recommended to further treat the patient with ezetimibe or a PCSK9i (alirocumab or evolocumab) to reach the LDL cholesterol reduction goal-that is, a decrease of 50% from the baseline.
In the current practice, the goal for statin and nonstatin therapies is to lower LDL cholesterol. Here, we argue that more aspects, rather than lowering LDL cholesterol alone, should be considered for statin and nonstatin therapies.
First, low LDL cholesterol is not always beneficial for health. For example, a study involving 118 160 participants who were older than 50 years reported that higher levels of LDL cholesterol were associated with a lower all-cause mortality in both male and female participants in each decade of age studied. The beneficial effect of higher LDL cholesterol on all-cause mortality was even seen in people with high levels of LDL cholesterol-that is, >4 mmol/L (>155 mg/dL). 2 Second, long-term side effects of lipid-lowering therapies need to be considered. It has been shown that treatment with pravastatin for 4 years was associated with more new cancer formation in humans (hazard ratio = 1.25; P = 0.02). 3 In particular, the pravastatin treatment increased the formation of breast cancer (hazard ratio = 1.65) and gastrointestinal cancer (hazard ratio = 1.46). 3 Therefore, aggressive lipid-lowering therapy in patients who do not present with atherosclerotic cardiovascular disease or diabetes mellitus might need to be reconsidered.
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